All sponsors

Incyte Corporation $INCY

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS36
PHASE 3 / 2-322
RECRUITING15
READOUTS ≤12 MONTHS12
READOUT SLIPPED >6 MO27%

Delay Index: of 30 active trials registered more than a year ago, 8 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Incyte Corporation on the live radar map → 📅 $INCY readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
InMIND
NCT04680052
P3Active, not recruitingFollicular Lymphoma; Marginal Zone Lymphoma6542024-02-23 (+8 mo)
MINDway
NCT05222555
P1/2Active, not recruitingDiffuse Large B Cell Lymphoma532024-07-17 (+2 mo)
Povorcitinib
NCT06113445
P3Active, not recruitingNonSegmental Vitiligo4672026-02-24 (-2 mo)
Povorcitinib
NCT06113471
P3Active, not recruitingNonSegmental Vitiligo4502026-03-17 (-2 mo)
firmMIND
NCT05429268
P3Active, not recruitingLarge B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma822026-03-30 (-9 mo)
TRuE-AD5
NCT06832618
P3Active, not recruitingAtopic Dermatitis1592026-08-07
frontMIND
NCT04824092
P3Active, not recruitingDiffuse Large B-cell Lymphoma8992026-09-01 (+15 mo)
Povorcitinib
NCT06516965
P3Active, not recruitingPrurigo Nodularis3462026-09-28
Axatilimab
NCT06388564
P2Active, not recruitingChronic Graft-versus-host-disease1302026-10-01 (-5 mo)
Ruxolitinib Cream
NCT06958211
P3Active, not recruitingHidradenitis Suppurativa5732026-10-01
Povorcitinib
NCT06516952
P3Active, not recruitingPrurigo Nodularis3492026-10-19
Ruxolitinib Cream
NCT06959225
P3Active, not recruitingHidradenitis Suppurativa5802026-10-29
Parsaclisib
NCT04509700
P2Active, not recruitingB-Cell Malignancies1122026-11-05 (+17 mo)
povorcitinib
NCT05851443
P2Active, not recruitingModerate to Severe Asthma2472026-11-20 (+16 mo)
STOP-HS LTE
NCT06212999
P3Active, not recruitingHidradenitis Suppurativa (HS)6172026-12-26
INCA034176
NCT06843408
P1/2Active, not recruitingChronic Graft-versus-host-disease322027-01-06 (+6 mo)
MAESTRA 1
NCT07023627
P2RecruitingOvarian Cancer1602027-04-27
Ruxolitinib Cream
NCT06804811
P3RecruitingNonSegmental Vitiligo2502027-04-30
Progress
NCT05090891
P2RecruitingFibrodysplasia Ossificans Progressiva (FOP)982027-07-30 (+45 mo)
Tafasitamab
NCT06465433
P2RecruitingHematologic Malignancies252027-08-29
INCA000585
NCT07104565
P2RecruitingImmune Thrombocytopenia562027-09-23
AXemplify-357
NCT06585774
P3RecruitingChronic Graft-versus-host-disease2402027-09-28
Ruxolitinib
NCT02955940
P2Active, not recruitingPancreatic Cancer; Colorectal Cancer (CRC)102027-09-30 (+107 mo)
MAESTRA 2
NCT07214779
P3Active, not recruitingOvarian Cancer132027-10-12 (-13 mo)
STOP-LTR
NCT06855498
P3RecruitingHidradenitis Suppurativa (HS)6002028-02-28
Povorcitinib
NCT07213973
P2RecruitingHidradenitis Suppurativa (HS)402028-03-25
INCA034176
NCT06821542
P3Active, not recruitingChronic Graft-versus-host-disease92028-05-31
TRuE-VIP1
NCT06548360
P3RecruitingNonSegmental Vitiligo1802028-06-05 (+22 mo)
DAWN-303
NCT07522073
P3RecruitingSolid Tumors5882028-09-15
INCA33890
NCT07284849
P3RecruitingCRC (Colorectal Cancer)7002028-12-29
INCA034176
NCT07124078
P2RecruitingChronic Graft-versus-host-disease602029-01-31
NEXERA-204
NCT07823322
P2RecruitingCRC (Colorectal Cancer)402029-05-14
EXCALIBUR-ET2
NCT07623200
P3RecruitingEssential Thrombocythemia4262029-06-15
Tacrolimus (Tac)
NCT06615050
P3RecruitingGraft-versus-host Disease (GVHD)5722031-01-17 (+3 mo)
FIGHT-214
NCT07862998
P2Not yet recruitingUnresectable Cholangiocarcinoma; Advanced/Metastatic Cholangiocarcinoma722031-02-25
MAESTRA 3
NCT07797283
P3Not yet recruitingOvarian Cancer5902032-05-01